Mingxia Jiang
Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, 100021, China
Beijing, 100021, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Turmoil and breakthroughs: Highlights and growing pains in breast cancer therapy 2025-2026.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: May 01, 2026
Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study.
Journal: BMC medicine
Published: February 08, 2026
Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study.
Journal: Breast cancer (Dove Medical Press)
Published: December 18, 2025
Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer.
Journal: The oncologist
Published: September 05, 2025
Safety Profile and Predictors of Adverse Events of Incadronate Disodium in Treating Breast Cancer Patients with Bone Metastases: A Retrospective Study.
Journal: Breast cancer (Dove Medical Press)
Published: February 18, 2025
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer.
Journal: Cancer biology & medicine
Published: September 13, 2024
Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study.
Journal: BMC cancer
Published: March 25, 2024
Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center study.
Journal: Therapeutic advances in medical oncology
Published: February 25, 2024
Adjuvant treatment strategy evolution and risk stratification for hormone receptor-positive, human epidermal growth factor receptor-2 negative early breast cancer in China.
Journal: The oncologist
Published: January 13, 2024
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: October 24, 2023
Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
Journal: Therapeutic advances in medical oncology
Published: June 14, 2023
Last Updated: 09/26/2026